McLeod Regional Medical Center installs Toshiba's Aquilion ONE to offer safe CT imaging to patients

A longtime partner of Toshiba, McLeod Regional Medical Center installed the AquilionTM ONE from Toshiba America Medical Systems, Inc. to offer the most advanced CT technology to its patients and become a leader in lowering radiation dose. McLeod is South Carolina's first Aquilion ONE user and the first site to implement Toshiba's PROTECT program. The Aquilion ONE is the eighth Toshiba CT system at McLeod Health and will act as the go-to scanner for emergency department patients, general radiology and cardiac exams.

“Toshiba developed PROTECT as a commitment to making CT imaging safer for all patients”

"At McLeod, we are driven to improve patient care by lowering radiation dose while maintaining high image quality, and the combination of Toshiba's Aquilion ONE CT system and the PROTECT program will help us achieve this mission," said David Poston, director, Radiology and Imaging, McLeod Regional Medical Center. "These technologies change the way we treat patients. For example, we are now imaging all cardiac patients with the Aquilion ONE, due to its ability to capture the heart in one rotation and show dynamic function, all at a low dose."

PROTECT is a three-year, comprehensive CT radiation dose management program combining Toshiba's technology solutions with its renowned education and support. Through in-person collaboration, Toshiba experts will review the system's hardware and software and consider implementation of additional dose reduction technologies.

"Toshiba developed PROTECT as a commitment to making CT imaging safer for all patients," said Satrajit Misra, senior director, CT Business Unit, Toshiba. "By providing our partners with technology, education and training we can continue to lower radiation dose with outstanding image quality."

Source:

Toshiba America Medical Systems, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials